SynthesisJournal of psychiatric research2022
Psychosis during the COVID-19 pandemic: A systematic review of case reports and case series.
Synthesis in Journal of psychiatric research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Prevalence and associated risk factors of psychotic experiences in the general population during the COVID-19 pandemic: a systematic review and meta-analysis.Annals of general psychiatry · 2026Article
- Comparison of Antipsychotics in the Treatment of COVID-19-Induced First-Episode Psychosis: A Review of Case Studies.Cureus · 2026Review
- Viral infections and risk of mental illness: A Mendelian randomization study.Brain, behavior, & immunity - health · 2025Article
- Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.Life (Basel, Switzerland) · 2025Review
- Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.Medicina (Kaunas, Lithuania) · 2025Observational
- Recurrent COVID-19-related psychotic disorder with neuro-immuno-endocrine dysfunction as a possible underlying mechanism: A case report from China.Brain, behavior, & immunity - health · 2024Article
- First-episode psychiatric disorder risk from SARS-CoV-2 infection: A clinical analysis with Chinese psychiatric inpatients.Journal of biomedical research · 2024Article
- Clinical Features and Prognosis of Coronavirus Disease 2019-Related Psychosis: A Retrospective Case Series.Alpha psychiatry · 2023Article
- The risk of hospitalization for psychotic disorders following hospitalization for COVID-19: a French nationwide longitudinal study.Molecular psychiatry · 2023Article
- Long COVID, the Brain, Nerves, and Cognitive Function.Neurology international · 2023Review
- New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report.BMC psychiatry · 2023Article
- COVID-19 psychosis versus psychosis due to cytotoxic lesion of the corpus callosum (CLOCC): A case report and review.Psychiatry research case reports · 2023Article
- Article
- COVID-19-Associated Acute Psychotic Disorder-Longitudinal Case Report and Brief Review of Literature.Medicina (Kaunas, Lithuania) · 2023Review
- COVID-19 and New-Onset Psychosis: A Comprehensive Review.Journal of personalized medicine · 2023Review
- The influence of alcohol consumption on Self-Rated Health and Mood during the COVID-19 pandemic in Spain.Frontiers in public health · 2023Article
- Case 34-2022: A 57-Year-Old Woman with Covid-19 and Delusions.The New England journal of medicine · 2022Article
- Impact of COVID-19 on Neuropsychiatric Disorders.Journal of clinical medicine · 2022Review
- Effect of the COVID-19 pandemic on the psychotropic drug consumption.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreliminary data suggest that patients with COVID-19 may experience psychiatric symptoms, including psychosis. We systematically reviewed the literature to evaluate the concurrence of new-onset psychosis or exacerbation of clinically stable psychosis through case reports and case series.
methodsSix databases were searched, followed by an electronic and manual search of the relevant articles. Studies were identified using predetermined eligibility criteria. We evaluated the demographic characteristics, clinical history, course of illness, management, and prognosis of the patients in these studies.
resultsCase reports and case series, altogether consisting of 57 unique cases were included. The mean patient age for onset of psychotic symptoms was 43.4 years for men and 40.3 years for women. About 69% of patients had no prior history of psychiatric disorders. Most patients had mild COVID-19-related symptoms, with only 15 (26.3%) presenting with moderate to severe COVID-19-related disease and complications. The most commonly reported psychotic symptoms were delusions and hallucinations. Patients with psychotic symptoms were treated with antipsychotics, benzodiazepines, valproic acid, and electroconvulsive treatment. In 36 cases, psychotic symptoms resolved completely or improved significantly. Ten cases had partial improvement with residual psychotic symptoms, and one patient died due to cardiac arrest.
conclusionMost patients responded to a low-to-moderate dose of antipsychotics with a quick recovery. However, the residual psychiatric symptoms highlight the need for careful monitoring and longer follow-up. Clinicians should be mindful of the occurrence of psychosis due to COVID-19 infection in a subset of COVID-19 patients that can be misdiagnosed as a psychotic disorder alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.